Clinical characteristics of NGT subjects in the different study populations in relation to LARS2 His324Gln polymorphism
| . | Hoorn study . | . | ERGO study . | . | DK2, Inter99 study . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| . | HH . | HQ + QQ . | HH . | HQ + QQ . | HH . | HQ + QQ . | |||
| n | 323 | 13 | 432 | 25 | 4,248 | 253 | |||
| Age (years) | 60 ± 7 | 61 ± 5 | 64 ± 5 | 66 ± 5* | 45.2 ± 7.8 | 44.6 ± 7.7 | |||
| Sex (male/female) | 128/195 | 4/9 | 238/194 | 11/14 | 1,964/2,284 | 130/123 | |||
| BMI (kg/m2) | 26.1 ± 3.0 | 25.7 ± 2.6 | 25.9 ± 3.2 | 25.2 ± 4.1 | 25.5 ± 4.1 | 25.3 ± 3.7 | |||
| HbA1c (%) | 5.5 ± 0.4 | 5.2 ± 0.4 | 5.8 ± 0.5 | 5.8 ± 0.7 | 5.8 ± 0.4 | 5.7 ± 0.4 | |||
| Fasting glucose (mmol/l) | 5.4 ± 0.5 | 5.1 ± 0.4 | 5.4 ± 0.4 | 5.4 ± 0.4 | 5.3 ± 0.4 | 5.3 ± 0.4 | |||
| 2-h glucose (mmol/l) | 5.2 ± 1.3 | 5.1 ± 1.3 | 5.3 ± 1.1 | 5.4 ± 1.1 | 5.5 ± 1.1 | 5.5 ± 1.2 | |||
| Fasting insulin (pmol/l) | 79 ± 36 | 71 ± 16 | 69 ± 34 | 69 ± 32 | 37 ± 23 | 39 ± 24 | |||
| 2-h insulin (pmol/l) | NA | NA | 60 ± 50 | 77 ± 56 | 168 ± 131 | 164 ± 124 | |||
| HOMA-IR | 19.0 ± 9.8 | 16.2 ± 3.7 | 17.0 ± 8.8 | 16.9 ± 9.0 | 8.9 ± 5.7 | 9.2 ± 5.7 | |||
| Cholesterol (mmol/l) | 6.6 ± 1.1 | 6.4 ± 1.1 | 6.6 ± 1.0 | 6.3 ± 1.2 | 5.4 ± 1.0 | 5.3 ± 1.0 | |||
| HDL (mmol/l) | 1.33 ± 0.34 | 1.50 ± 0.65 | 1.34 ± 0.33 | 1.31 ± 0.37 | 1.46 ± 0.40 | 1.40 ± 0.37† | |||
| Triglycerides (mmol/l) | 1.41 ± 0.67 | 1.38 ± 0.58 | 1.48 ± 0.62 | 1.70 ± 1.03 | 1.19 ± 0.95 | 1.14 ± 0.79 | |||
| Free fatty acids (mmol/l) | 0.58 ± 0.21 | 0.55 ± 0.17 | 0.29 ± 0.09 | 0.34 ± 0.12* | NA | NA | |||
| . | Hoorn study . | . | ERGO study . | . | DK2, Inter99 study . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| . | HH . | HQ + QQ . | HH . | HQ + QQ . | HH . | HQ + QQ . | |||
| n | 323 | 13 | 432 | 25 | 4,248 | 253 | |||
| Age (years) | 60 ± 7 | 61 ± 5 | 64 ± 5 | 66 ± 5* | 45.2 ± 7.8 | 44.6 ± 7.7 | |||
| Sex (male/female) | 128/195 | 4/9 | 238/194 | 11/14 | 1,964/2,284 | 130/123 | |||
| BMI (kg/m2) | 26.1 ± 3.0 | 25.7 ± 2.6 | 25.9 ± 3.2 | 25.2 ± 4.1 | 25.5 ± 4.1 | 25.3 ± 3.7 | |||
| HbA1c (%) | 5.5 ± 0.4 | 5.2 ± 0.4 | 5.8 ± 0.5 | 5.8 ± 0.7 | 5.8 ± 0.4 | 5.7 ± 0.4 | |||
| Fasting glucose (mmol/l) | 5.4 ± 0.5 | 5.1 ± 0.4 | 5.4 ± 0.4 | 5.4 ± 0.4 | 5.3 ± 0.4 | 5.3 ± 0.4 | |||
| 2-h glucose (mmol/l) | 5.2 ± 1.3 | 5.1 ± 1.3 | 5.3 ± 1.1 | 5.4 ± 1.1 | 5.5 ± 1.1 | 5.5 ± 1.2 | |||
| Fasting insulin (pmol/l) | 79 ± 36 | 71 ± 16 | 69 ± 34 | 69 ± 32 | 37 ± 23 | 39 ± 24 | |||
| 2-h insulin (pmol/l) | NA | NA | 60 ± 50 | 77 ± 56 | 168 ± 131 | 164 ± 124 | |||
| HOMA-IR | 19.0 ± 9.8 | 16.2 ± 3.7 | 17.0 ± 8.8 | 16.9 ± 9.0 | 8.9 ± 5.7 | 9.2 ± 5.7 | |||
| Cholesterol (mmol/l) | 6.6 ± 1.1 | 6.4 ± 1.1 | 6.6 ± 1.0 | 6.3 ± 1.2 | 5.4 ± 1.0 | 5.3 ± 1.0 | |||
| HDL (mmol/l) | 1.33 ± 0.34 | 1.50 ± 0.65 | 1.34 ± 0.33 | 1.31 ± 0.37 | 1.46 ± 0.40 | 1.40 ± 0.37† | |||
| Triglycerides (mmol/l) | 1.41 ± 0.67 | 1.38 ± 0.58 | 1.48 ± 0.62 | 1.70 ± 1.03 | 1.19 ± 0.95 | 1.14 ± 0.79 | |||
| Free fatty acids (mmol/l) | 0.58 ± 0.21 | 0.55 ± 0.17 | 0.29 ± 0.09 | 0.34 ± 0.12* | NA | NA | |||
Data are means ± SD. Three QQ homozygotes were detected in the DK2 cohort. P values were obtained after general linear regression (SPSS), with age and BMI as covariates and sex and genotype as fixed factors.
P ≤ 0.01,
P ≤ 0.05. HOMA-IR, homeostasis model assessment of insulin resistance.